Low chikungunya virus seroprevalence two years after emergence in Fiji.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 11 07 2019
revised: 28 10 2019
accepted: 30 10 2019
pubmed: 7 11 2019
medline: 24 3 2020
entrez: 6 11 2019
Statut: ppublish

Résumé

In Fiji, autochthonous chikungunya virus (CHIKV) infection was first detected in March 2015. In a previous serosurvey conducted during October-November 2015, we reported a prevalence of anti-CHIKV IgG antibodies of 0.9%. In the present study, we investigated the seroprevalence of CHIKV two years after its emergence in Fiji. Sera from 320 residents of Fiji recruited in June 2017, from the same cohort of individuals that participated in the serosurvey in 2015, were tested for the presence of IgG antibodies against CHIKV using a recombinant antigen-based microsphere immunoassay. Between 2015 and 2017, CHIKV seroprevalence among residents increased from 0.9% (3/333) to 12.8% (41/320). Of the participants with available serum samples collected in both 2015 and 2017 (n=200), 31 (15.5%) who were seronegative in 2015 had seroconverted to CHIKV in 2017. Our findings suggest that low-level transmission of CHIKV occurred during the two years following the emergence of the virus in Fiji. No CHIKV infection has been reported in Fiji since 2017, but due to the presumed low herd immunity of the population, the risk of CHIKV re-emergence is high. Consequently, chikungunya should be considered in the differential diagnosis of acute febrile diseases in Fiji.

Identifiants

pubmed: 31689529
pii: S1201-9712(19)30434-5
doi: 10.1016/j.ijid.2019.10.040
pmc: PMC6912130
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

223-225

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

J Virol. 2010 Aug;84(16):8021-32
pubmed: 20519386
Emerg Infect Dis. 2017 Oct;23(10):1751-1753
pubmed: 28930020
Emerg Infect Dis. 2019 Apr;25(4):827-830
pubmed: 30882332
Emerg Infect Dis. 2019 Aug;25(8):1535-1538
pubmed: 31310218
Emerg Infect Dis. 2015 Apr;21(4):724-6
pubmed: 25811534
PLoS Biol. 2019 Jan 22;17(1):e3000130
pubmed: 30668574
Emerg Infect Dis. 2018 Mar;24(3):558-561
pubmed: 29460745

Auteurs

Maite Aubry (M)

Institut Louis Malardé, PO BOX 30, 98713 Papeete, Tahiti, French Polynesia. Electronic address: maubry@ilm.pf.

Mike Kama (M)

Fiji Centre for Communicable Disease Control, Tamavua Hospital Complex, Mataika House, Suva, Fiji; The University of the South Pacific, Private Mail Bag, Laucala Campus, Suva, Fiji.

Alasdair D Henderson (AD)

London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom.

Anita Teissier (A)

Institut Louis Malardé, PO BOX 30, 98713 Papeete, Tahiti, French Polynesia.

Jessica Vanhomwegen (J)

Institut Pasteur, 25-28, rue du Docteur Roux 75724 Paris Cedex 15, France.

Teheipuaura Mariteragi-Helle (T)

Institut Louis Malardé, PO BOX 30, 98713 Papeete, Tahiti, French Polynesia.

Tuterarii Paoaafaite (T)

Institut Louis Malardé, PO BOX 30, 98713 Papeete, Tahiti, French Polynesia.

Jean-Claude Manuguerra (JC)

Institut Pasteur, 25-28, rue du Docteur Roux 75724 Paris Cedex 15, France.

Ketan Christi (K)

The University of the South Pacific, Private Mail Bag, Laucala Campus, Suva, Fiji.

Conall H Watson (CH)

London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom; Epidemic Research Group Oxford, University of Oxford, Oxford OX3 7BN, United Kingdom.

Colleen L Lau (CL)

Research School of Population Health, The Australian National University, 62 Mills Road, Acton, ACT 2601, Australia.

Adam J Kucharski (AJ)

London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom.

Van-Mai Cao-Lormeau (VM)

Institut Louis Malardé, PO BOX 30, 98713 Papeete, Tahiti, French Polynesia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH